TELA BIO, INC. (TELA): Price and Financial Metrics

TELA BIO, INC. (TELA): $5.17

0.20 (+4.02%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TELA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#255 of 363

in industry

TELA Price/Volume Stats

Current price $5.17 52-week high $11.26
Prev. close $4.97 52-week low $4.23
Day low $5.02 Volume 106,800
Day high $5.19 Avg. volume 136,085
50-day MA $6.03 Dividend yield N/A
200-day MA $7.09 Market Cap 127.44M

TELA Stock Price Chart Interactive Chart >


TELA BIO, INC. (TELA) Company Bio


TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.


TELA Latest News Stream


Event/Time News Detail
Loading, please wait...

TELA Latest Social Stream


Loading social stream, please wait...

View Full TELA Social Stream

Latest TELA News From Around the Web

Below are the latest news stories about TELA BIO INC that investors may wish to consider to help them evaluate TELA as an investment opportunity.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,175 shares of its common stock

Yahoo | December 15, 2023

TELA Bio to Take Part in Connecting the Dots

MALVERN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, announced today that it took part in a segment in Connecting the Dots, a series of branded films presented by MedTech Europe and including a film produced for them by BBC StoryWorks Commercial Pr

Yahoo | December 5, 2023

TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference

MALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 35th Annual Healthcare Confere

Yahoo | November 16, 2023

TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript

TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good day and thank you for standing by, and welcome to the TELA Bio Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today’s conference call is being recorded. I […]

Yahoo | November 12, 2023

TELA Bio Reports Third Quarter 2023 Financial Results

MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue of $15.1 million in the third quarter, representing growth of 35% over the third quarter o

Yahoo | November 9, 2023

Read More 'TELA' Stories Here

TELA Price Returns

1-mo -3.36%
3-mo -24.14%
6-mo -9.62%
1-year -43.99%
3-year -61.93%
5-year N/A
YTD -21.90%
2023 -42.43%
2022 -10.16%
2021 -14.89%
2020 16.14%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!